Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4⁺ T cells

References

• Deeks SG. HIV: Shock and kill. Nature. 2012;487(7408):439–440.
   PubMed Web of Science ®Google Scholar
• Kim Y, Anderson JL, Lewin SR. Getting the “kill” into “shock and kill": strategies to eliminate latent HIV. Cell Host Microbe. 2018;23(1):14–26.
   PubMed Web of Science ®Google Scholar
• Margolis DM, Archin NM, Cohen MS, et al. Curing HIV: seeking to target and clear persistent infection. Cell. 2020;181(1):189–206.
   PubMed Web of Science ®Google Scholar
• Ait-Ammar A, Kula A, Darcis G, et al. Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Front Microbiol. 2019;10:3060.
   PubMed Web of Science ®Google Scholar
• Jiang C, Lian X, Gao C, et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020;585(7824):261–267.
   PubMed Web of Science ®Google Scholar
• Salahong T, Schwartz C, Sungthong R. Are BET inhibitors yet promising latency-reversing agents for HIV-1 reactivation in AIDS therapy? Viruses. 2021;13(6).
   PubMed Web of Science ®Google Scholar
• Lopes JR, Chiba DE, Dos Santos JL. HIV latency reversal agents: a potential path for functional cure? Eur J Med Chem. 2021;213:113213.
   PubMed Web of Science ®Google Scholar
• Acchioni C, Palermo E, Sandini S, et al. Fighting HIV-1 persistence: at the crossroads of “shoc-K and B-lock”. Pathogens. 2021;10(11).
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Siliciano RF. Low inducibility of latent human immunodeficiency virus type 1 proviruses as a major Barrier to cure. J Infect Dis. 2021;223(12 Suppl 2):13–21.
   PubMed Web of Science ®Google Scholar
• Nixon CC, Mavigner M, Sampey GC, et al. Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo. Nature. 2020;578(7793):160–165.
   PubMed Web of Science ®Google Scholar
• McBrien JB, Mavigner M, Franchitti L, et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020;578(7793):154–159.
   PubMed Web of Science ®Google Scholar
• Smillie KJ, Cousin MA. The role of GSK3 in presynaptic function. Int J Alzheimers Dis. 2011;2011:263673.
   PubMedGoogle Scholar
• Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics. 2016;6(4):571–593.
   PubMed Web of Science ®Google Scholar
• Palomo V, Martinez A. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin Ther Pat. 2017;27(6):657–666.
   PubMed Web of Science ®Google Scholar
• Sahin I, Eturi A, De Souza A, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther. 2019;20(8):1047–1056.
   PubMed Web of Science ®Google Scholar
• Medic B, Stojanovic M, Stimec BV, et al. Lithium - pharmacological and toxicological aspects: the Current state of the art. Curr Med Chem. 2020;27(3):337–351.
   PubMed Web of Science ®Google Scholar
• Mathuram TL, Reece LM, Cherian KM. GSK-3 Inhibitors: a double-edged sword? - An update on Tideglusib. Drug Res (Stuttg). 2018;68(8):436–443.
   PubMed Web of Science ®Google Scholar
• Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999.
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26.
   PubMed Web of Science ®Google Scholar
• Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5(9):691–701.
   PubMed Web of Science ®Google Scholar
• Cai J, Gao H, Zhao J, et al. Infection with a newly designed dual fluorescent reporter HIV-1 effectively identifies latently infected CD4(+) T cells. Elife. 2021:10:e63810.
   PubMed Web of Science ®Google Scholar
• Ma L, Jiang QA, Sun L, et al. X-linked RNA-binding motif protein modulates HIV-1 infection of CD4(+) T cells by maintaining the trimethylation of histone H3 lysine 9 at the downstream region of the 5’ long terminal repeat of HIV proviral DNA. mBio. 2020;11(2):e03424-19.
   PubMed Web of Science ®Google Scholar
• Sun L, Peng Y, Yu W, et al. Mechanistic insight into antiretroviral potency of 2'-deoxy-2'-beta-fluoro-4'-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention. J Med Chem. 2020;63(15):8554–8566.
   PubMed Web of Science ®Google Scholar
• Yang Q, Feng F, Li P, et al. Arsenic trioxide impacts viral latency and delays viral rebound after termination of ART in chronically SIV-infected macaques. Adv Sci (Weinh). 2019;6(13):1900319.
   PubMedGoogle Scholar
• Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 2001;280(3):720–725.
   PubMed Web of Science ®Google Scholar
• Folks TM, Justement J, Kinter A, et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238(4828):800–802.
   PubMed Web of Science ®Google Scholar
• Cadigan KM, Waterman ML. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;4(11):a007906.
   PubMed Web of Science ®Google Scholar
• Bime C, Pouladi N, Sammani S, et al. Genome-Wide Association Study in African Americans with acute respiratory distress syndrome identifies the selectin P ligand gene as a risk factor. Am J Resp Crit Care. 2018;197(11):1421–1432.
   PubMed Web of Science ®Google Scholar
• Zhu J, Gaiha GD, John SP, et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012;2(4):807–816.
   PubMed Web of Science ®Google Scholar
• Johnson JL, Georgakilas G, Petrovic J, et al. Lineage-determining transcription factor TCF-1 initiates the epigenetic identity of T cells. Immunity. 2018;48(2):243–257.e10.
   PubMed Web of Science ®Google Scholar
• Sun WW, Jiao S, Sun L, et al. SUN2 Modulates HIV-1 infection and latency through association with lamin A/C to maintain the repressive chromatin. MBio. 2018;9(3):e02408–17.
   PubMed Web of Science ®Google Scholar
• Qu D, Sun WW, Li L, et al. Long noncoding RNA MALAT1 releases epigenetic silencing of HIV-1 replication by displacing the polycomb repressive complex 2 from binding to the LTR promoter. Nucleic Acids Res. 2019;47(6):3013–3027.
   PubMed Web of Science ®Google Scholar
• Yang H, Li X, Yang X, et al. Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections. Antiviral Res. 2019;169:104555.
   PubMed Web of Science ®Google Scholar
• Jean LeBlanc N, Menet R, Picard K, et al. Canonical Wnt pathway maintains blood-brain barrier integrity upon ischemic stroke and its activation ameliorates tissue plasminogen activator therapy. Mol Neurobiol. 2019;56(9):6521–6538.
   PubMed Web of Science ®Google Scholar
• Sato N, Meijer L, Skaltsounis L, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10(1):55–63.
   PubMed Web of Science ®Google Scholar
• Suresh SN, Chavalmane AK, Dj V, et al. A novel autophagy modulator 6-bio ameliorates SNCA/alpha-synuclein toxicity. Autophagy. 2017;13(7):1221–1234.
   PubMed Web of Science ®Google Scholar
• Azeem W, Bakke RM, Appel S, et al. Dual pro- and anti-inflammatory features of monocyte-derived dendritic cells. Front Immunol. 2020;11:438.
   PubMed Web of Science ®Google Scholar
• Pinto D, Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res. 2005;306(2):357–363.
   PubMed Web of Science ®Google Scholar
• Bafico A, Liu G, Goldin L, et al. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell. 2004;6(5):497–506.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hartmann H, Do VM, et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 1998;395(6703):698–702.
   PubMed Web of Science ®Google Scholar
• Zhang X, Hao J. Development of anticancer agents targeting the Wnt/beta-catenin signaling. Am J Cancer Res. 2015;5(8):2344–2360.
   PubMed Web of Science ®Google Scholar
• Fuentes RG, Arai MA, Ishibashi M. Natural compounds with Wnt signal modulating activity. Nat Prod Rep. 2015;32(12):1622–1628.
   PubMed Web of Science ®Google Scholar
• Libro R, Bramanti P, Mazzon E. The role of the Wnt canonical signaling in neurodegenerative diseases. Life Sci. 2016;158:78–88.
   PubMed Web of Science ®Google Scholar
• Serafino A, Sferrazza G, Colini Baldeschi A, et al. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases. Expert Opin Drug Discov. 2017;12(2):169–186.
   PubMed Web of Science ®Google Scholar
• Mavigner M, Zanoni M, Tharp GK, et al. Pharmacological modulation of the Wnt/beta-catenin pathway inhibits proliferation and promotes differentiation of long-lived memory CD4(+) T cells in antiretroviral therapy-suppressed simian immunodeficiency virus-infected macaques. J Virol. 2019;94(1):e01094–19.
   PubMed Web of Science ®Google Scholar
• Henderson LJ, Narasipura SD, Adarichev V, et al. Identification of novel T cell factor 4 (TCF-4) binding sites on the HIV long terminal repeat which associate with TCF-4, beta-catenin, and SMAR1 to repress HIV transcription. J Virol. 2012;86(17):9495–9503.
   PubMed Web of Science ®Google Scholar
• Henderson LJ, Sharma A, Monaco MC, et al. Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription through its intact core and cysteine-rich domains inhibits Wnt/beta-catenin signaling in astrocytes: relevance to HIV neuropathogenesis. J Neurosci. 2012;32(46):16306–16313.
   PubMed Web of Science ®Google Scholar
• Narasipura SD, Henderson LJ, Fu SW, et al. Role of beta-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes. J Virol. 2012;86(4):1911–1921.
   PubMed Web of Science ®Google Scholar
• Kumar A, Zloza A, Moon RT, et al. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol. 2008;82(6):2813–2820.
   PubMed Web of Science ®Google Scholar
• Wortman B, Darbinian N, Sawaya BE, et al. Evidence for regulation of long terminal repeat transcription by Wnt transcription factor TCF-4 in human astrocytic cells. J Virol. 2002;76(21):11159–11165.
   PubMed Web of Science ®Google Scholar
• Henderson LJ, Al-Harthi L. Role of beta-catenin/TCF-4 signaling in HIV replication and pathogenesis: insights to informing novel anti-HIV molecular therapeutics. J Neuroimmune Pharmacol. 2011;6(2):247–259.
   PubMed Web of Science ®Google Scholar
• Aljawai Y, Richards MH, Seaton MS, et al. Beta-catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection. Curr HIV Res. 2014;12(3):164–173.
   PubMed Web of Science ®Google Scholar
• Kehn-Hall K, Guendel I, Carpio L, et al. Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology. 2011;415(1):56–68.
   PubMed Web of Science ®Google Scholar
• Sheridan PL, Sheline CT, Cannon K, et al. Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA in vitro. Genes Dev. 1995;9(17):2090–2104.
   PubMed Web of Science ®Google Scholar
• Waterman ML, Fischer WH, Jones KA. A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev. 1991;5(4):656–669.
   PubMed Web of Science ®Google Scholar